ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is expected to report third quarter earnings results, after market close, on Wednesday 4th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.38 per share.
Looking ahead, the full year loss are expected at $ 1.66 per share on the revenues of $ 443.75 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 430.00 million ~ $ 450.00 million
Click Here For More Historical Outlooks Of ACADIA Pharmaceuticals Inc.
Previous Quarter Performance
ACADIA Pharmaceuticals Inc. recorded loss for the second quarter of $ 0.27 per share, from the revenue of $ 110.10 million. The quarterly revenues increased 32.32 percent compared with the same quarter last year. According to street consensus, ACAD was expected to report 2Q20 loss of $ 0.44 per share from revenue of $ 103.34 million. The bottom line results beat street analysts by $ 0.17 or 38.64 percent, at the same time, top line results outshined analysts by $ 6.76 million or 6.54 percent.
Stock Performance
Shares of ACADIA Pharmaceuticals Inc. traded up $ 0.96 or 2.10 percent on Tuesday, reaching $ 46.60 with volume of 770.90 thousand shares. ACADIA Pharmaceuticals Inc. has traded high as $ 46.92 and has cracked $ 45.36 on the downward trend
According to the previous trading day, closing price of $ 46.60, representing a 52.03 % increase from the 52 week low of $ 30.02 and a 22.28 % decrease over the 52 week high of $ 58.72.
The company has a market capital of $ 7.40 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 13th October 2020, maintained by Morgan Stanley at Overweight rating, with $ 57.00 target price.
Conference Call
ACADIA Pharmaceuticals Inc. will be hosting a conference call at 4:30 PM eastern time on 4th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.acadia-pharm.com
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinsons disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder.
